Olympus Launches Venture Capital Fund To Strengthen Medtech Leadership
Olympus Corporation has launched Olympus Innovation Ventures, a venture capital fund dedicated to investing in startups that enhance clinical outcomes and reduce healthcare costs.
The fund allocates $50 million for early- and growth-stage investments in areas like gastroenterology and urology. Olympus aims to leverage its clinical expertise and market access to help portfolio companies succeed.
This initiative underscores Olympus' commitment to minimally invasive surgery and advancing medical technology, aligning with its 100-year history of innovation.
- Launch of Olympus Innovation Ventures to invest in innovative healthcare startups.
- $50 million allocated for initial and follow-on investments.
- Focus on early- and growth-stage companies in high-impact therapeutic areas.
- Strategic involvement of Touchdown Ventures to manage the fund and enhance its effectiveness.
- None.
TOKYO and CENTER VALLEY, Pa., Nov. 11, 2021 /PRNewswire/ -- Olympus Corporation (Tokyo: 7733), a global leader in medical technology, has announced the establishment of Olympus Innovation Ventures to invest in pioneering startups with innovative technologies that improve clinical outcomes, reduce healthcare costs and enhance the quality of life for patients.
Olympus Innovation Ventures, a fully owned subsidiary of Olympus Corporation of the Americas, is a venture capital fund focused on startups poised to improve patient outcomes, radically advance the detection and treatment of disease, and transform the surgery suite. The new fund expands upon Olympus' strategy to strengthen endoscopy and pioneer next-generation tools and procedures for minimally invasive surgery.
Olympus' venture fund is stage-agnostic, prioritizing early- and growth-stage companies globally with solutions in therapeutic areas including gastroenterology, respiratory, and urology. Olympus has allocated
For more information, please visit https://olympusamerica.com/venture-capital. Olympus Innovation Ventures can be contacted at ventures@olympus.com.
Olympus has been a leader in optical and medical innovation for over 100 years, introducing a mass-produced microscope to Japan in 1919 and the world's first gastrocamera for practical use in 1950. Olympus' tools have aided the minimally invasive surgery revolution and have evolved to detect and treat disease. Yasuo Takeuchi, CEO of Olympus Corporation, says "Our investment underscores our commitment to make people's lives safer, healthier, and more fulfilling. Our goal is for this fund to continue our history of innovation and support our long-term growth and transformation."
Touchdown Ventures, a firm specializing in corporate venture capital, will help manage the Olympus Innovation Ventures fund. Touchdown will work closely with senior executives of Olympus in all aspects of operating the fund.
"We are excited about what Olympus can bring to entrepreneurs through the company's technical strengths, industry relationships, vast distribution, and deep subject matter expertise," noted Scott Lenet, co-founder and President of Touchdown Ventures. "The entire Olympus Innovation Ventures team is working to be the partner of choice for innovators and create a competitive advantage for their startups."
Nacho Abia, Chief Operating Officer of Olympus Corporation, said "This effort is another way Olympus is demonstrating its commitment to excellence and creating tangible value for providers and patients. We believe we will play a meaningful role in the advancement of minimally invasive care and new ways to detect, monitor and treat conditions and diseases."
About Olympus
Olympus is passionate about creating customer-driven solutions for the medical, life sciences, and industrial equipment industries. For more than 100 years, Olympus has focused on making people's lives healthier, safer and more fulfilling by helping to detect, prevent, and treat disease; furthering scientific research; and ensuring public safety. As a leading medical technology company, our Medical business uses innovative capabilities in medical technology, therapeutic intervention, and precision manufacturing to help healthcare professionals deliver diagnostic, therapeutic, and minimally invasive procedures to improve clinical outcomes, reduce overall costs, and enhance the quality of life for patients and their safety. Olympus' Medical portfolio includes endoscopes, laparoscopes, and video imaging systems, as well as surgical energy devices, system integration solutions, medical services, and a wide range of endotherapy instruments for endoscopic and therapeutic applications. For more information, visit www.olympus-global.com.
About Touchdown Ventures
Touchdown Ventures partners with corporations to manage their venture capital programs. Touchdown works closely with each corporation to achieve the financial and strategic benefits from venture capital investments. The firm is a Registered Investment Adviser and maintains offices in Los Angeles, Philadelphia, and San Francisco. More information on Touchdown can be found at www.touchdownvc.com
Safe Harbor Statement
This press release contains statements that reflect our views about our future performance and constitute "forward-looking statements" under the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "outlook," "believe," "anticipate," "appear," "may," "will," "should," "intend," "plan," "estimate," "expect," "assume," "seek," "forecast," and similar references to future periods. Our views about future performance involve risks and uncertainties that are difficult to predict and, accordingly, our actual results may differ materially from the results discussed in our forward-looking statements. We caution you against relying on any of these forward-looking statements.
Our future performance may be affected by the levels of residential repair and remodel activity and, to a lesser extent, new home construction, our ability to maintain our strong brands and reputation and to develop innovative products, our ability to maintain our competitive position in our industries, our reliance on key customers, the length and severity of the ongoing COVID-19 pandemic, including its impact on domestic and international economic activity, consumer confidence, our production capabilities, our employees and our supply chain; the cost and availability of materials and the imposition of tariffs, our dependence on third-party suppliers, risks associated with our international operations and global strategies, our ability to achieve the anticipated benefits of our strategic initiatives, our ability to successfully execute our acquisition strategy and integrate businesses that we have and may acquire, our ability to attract, develop and retain talented and diverse personnel, risks associated with our reliance on information systems and technology, and our ability to achieve the anticipated benefits from our investments in new technology. These and other factors are discussed in detail in our most recent Annual Report on Form 10-K, as well as in our Quarterly Reports on Form 10-Q and in other filings we make with the Securities and Exchange Commission. Any forward-looking statement made by us speaks only as of the date on which it was made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Unless required by law, we undertake no obligation to update publicly any forward-looking statements as a result of new information, future events or otherwise.
View original content to download multimedia:https://www.prnewswire.com/news-releases/olympus-launches-venture-capital-fund-to-strengthen-medtech-leadership-301422685.html
SOURCE Olympus
FAQ
What is Olympus Innovation Ventures?
How much has Olympus allocated for its venture capital fund?
Which therapeutic areas does Olympus Innovation Ventures focus on?
Who is managing Olympus Innovation Ventures?
What is the goal of Olympus Innovation Ventures?
When was Olympus Innovation Ventures launched?
